Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
Antonio Jimeno(Johns Hopkins University), Manuel Hidalgo(Spanish National Cancer Research Centre)
Cited by 83
Related Papers
An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
|Clinical Cancer Research|2006|412
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
|British Journal of Cancer|2013|291
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
|Molecular Cancer Therapeutics|2010|246